namilumab: Clinical Trials

8 trials of namilumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated. 6 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 3, Terminated 3
Phase 12Completed 2

Follow namilumab: new trials by email Literature Review of namilumab trials Research Report on namilumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Namilumab, Placebo - Sarcoidosis, Pulmonary
Phase 2TerminatedKinevant Sciences GmbH1072022-08-312025-09-12
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Namilumab - Sarcoidosis, Cardiac
Phase 2TerminatedKinevant Sciences GmbH12022-08-232025-04-17
Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis
Placebo, Namilumab - Axial Spondyloarthritis
Phase 2CompletedIzana Bioscience Ltd.422018-09-062022-03-08
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Namilumab, Adalimumab, Methotrexate - Rheumatoid Arthritis
Phase 2TerminatedTakeda72015-04-082019-02-05
Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Namilumab, Placebo, Methotrexate - Rheumatoid Arthritis
Phase 2CompletedTakeda1082014-12-172018-09-14
Single-Dose Study of MT203
MT203 80 mg or matching Placebo, MT203 150mg or matching Placebo, MT203 300 mg or matching placebo - Healthy Volunteers
Phase 1CompletedTakeda322014-11-012016-06-20
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
Namilumab, Placebo - Plaque Psoriasis
Phase 2CompletedTakeda1222014-06-012017-04-07
A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis
namilumab (MT203), Placebo - Rheumatoid Arthritis
Phase 1CompletedTakeda242011-03-012015-08-20

Conditions studied

Arthritis, Rheumatoid (3)  ·  Axial Spondyloarthritis (1)  ·  Sarcoidosis (1)  ·  Sarcoidosis, Pulmonary (1)

Sponsors

Takeda (5)  ·  Kinevant Sciences GmbH (2)  ·  Izana Bioscience Ltd. (1)

Countries

United Kingdom (4)  ·  Bulgaria (2)  ·  Czechia (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Russia (2)  ·  Spain (2)  ·  United States (2)  ·  Belgium (1)  ·  Canada (1)  ·  Estonia (1)  ·  France (1)  ·  Germany (1)  ·  Poland (1)  ·  South Korea (1)

Top investigators

Peter C Taylor, PhD (1)

Results publications

PMID 28274253, PMID 30168415, PMID 30207587, PMID 30999929, PMID 38942047, PMID 41819539

NIH funding

2014 (1)